| Geld/Brief | - / - |
| Spread | - |
| Schluss Vortag | 0,051 $ |
| Gehandelte Stücke | 455 |
| Tagesvolumen Vortag | 40,36 $ |
| Tagestief 0,051 $ Tageshoch 0,051 $ | |
| 52W-Tief 0,027 $ 52W-Hoch 0,801 $ | |
| Jahrestief 0,027 $ Jahreshoch 0,801 $ | |
| Handelsplatz | Letzter | Änderung | Vortag | Zeit | |
|---|---|---|---|---|---|
| Berlin | 0,226 € | 0 % | 0,226 € | 14.05.24 | |
| Nasdaq OTC Other | 0,051 $ | 0 % | 0,051 $ | 12.12.25 | |
| Datum | Kurs | Volumen |
|---|---|---|
| 12.12.25 | 0,051 | 25 |
| 11.12.25 | 0,051 | 40 |
| 10.12.25 | 0,0891 | 45 |
| 09.12.25 | 0,0401 | 16 |
| 04.12.25 | 0,1036 | 15 |
| Zeitraum | Kurs | % |
|---|---|---|
| 1 Woche | 0,1036 $ | -50,77% |
| 1 Monat | 0,0401 $ | +27,18% |
| 6 Monate | 0,1203 $ | -57,61% |
| 1 Jahr | 0,027 $ | +88,89% |
| 5 Jahre | - | - |
| Marktkapitalisierung | 1,85 Mio. € |
| Aktienanzahl | 42,59 Mio. |
| Währung | EUR |
| Land | USA |
| Sektor | Gesundheit |
| Branche | Biotechnologie |
| Aktientyp | Stammaktie |
Merger mit Biosight
-Combined Company Will Operate as Biosight Therapeutics to Advance Pipeline of Clinical-Stage Oncology Programs with Lead Program Aspacytarabine (BST-236) in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
-Combined Company Will be Well-Funded with Cash Position of approx.$50 Million Expected at Closing
-Multiple Clinical and Regulatory Pipeline Milestones Planned for Combined Company Over the Next 12-18 Months
https://www.advaxis.com/news-releases/news-release-details/advaxis-and-biosight-announce-entry-definitive-merger-agreement